Lauren C Y Tang, John D Chetwood, Mandy S M Lai, Terry C F Yip, Rena Cao, Elizabeth Powter, Shirin Salimi, Rodger Wu, Andrew Coulshed, David G Bowen, Simone I Strasser, Talal Valliani, Michael Crawford, Carlo Pulitano, Catriona McKenzie, James Kench, Geoffrey W McCaughan, Ken Liu
{"title":"Incidence, epidemiology, and outcomes of acute allograft rejection following liver transplantation in Australia.","authors":"Lauren C Y Tang, John D Chetwood, Mandy S M Lai, Terry C F Yip, Rena Cao, Elizabeth Powter, Shirin Salimi, Rodger Wu, Andrew Coulshed, David G Bowen, Simone I Strasser, Talal Valliani, Michael Crawford, Carlo Pulitano, Catriona McKenzie, James Kench, Geoffrey W McCaughan, Ken Liu","doi":"10.1097/LVT.0000000000000375","DOIUrl":null,"url":null,"abstract":"<p><p>Acute allograft rejection is a well-known complication of liver transplantation (LT). The incidence, epidemiology, and outcomes of acute rejection have not been well described in Australia. We retrospectively studied consecutive adults who underwent deceased donor LT at a single center between 2010 and 2020. Donor and recipient data at the time of LT and recipient outcomes were collected from a prospective LT database. Liver biopsy reports were reviewed, and only a graft's first instance of biopsy-proven acute rejection was analyzed. During the study period, 796 liver transplants were performed in 770 patients. Biopsy-proven rejection occurred in 34.9% of transplants. There were no significant changes in the incidence of rejection over time (linear trend p =0.11). The median time to the first episode of rejection was 71 days after LT: 2.2% hyperacute, 50.4% early (≤90 d), and 47.5% late rejection (>90 d). Independent risk factors for rejection were younger recipient age at transplant (aHR 0.98 per year increase, 95% CI: 0.97-1.00, p =0.01), and ABO-incompatible grafts (aHR 2.55 vs. ABO-compatible, 95% CI: 1.27-5.09, p <0.01) while simultaneous multiorgan transplants were protective (aHR 0.21 vs. LT only, 95% CI: 0.08-0.58, p <0.01). Development of acute rejection (both early and late) was independently associated with significantly reduced graft (aHR 3.13, 95% CI: 2.21-4.42, p <0.001) and patient survival (aHR 3.42, 95% CI: 2.35-4.98, p <0.001). In this 11-year Australian study, acute LT rejection occurred in 35%, with independent risk factors of younger recipient age and ABO-incompatible transplant, while having a simultaneous multiorgan transplant was protective. Acute rejection was independently associated with reduced graft and patient survival after adjustment for other factors.</p>","PeriodicalId":18072,"journal":{"name":"Liver Transplantation","volume":null,"pages":null},"PeriodicalIF":4.7000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Liver Transplantation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/LVT.0000000000000375","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/4/23 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Acute allograft rejection is a well-known complication of liver transplantation (LT). The incidence, epidemiology, and outcomes of acute rejection have not been well described in Australia. We retrospectively studied consecutive adults who underwent deceased donor LT at a single center between 2010 and 2020. Donor and recipient data at the time of LT and recipient outcomes were collected from a prospective LT database. Liver biopsy reports were reviewed, and only a graft's first instance of biopsy-proven acute rejection was analyzed. During the study period, 796 liver transplants were performed in 770 patients. Biopsy-proven rejection occurred in 34.9% of transplants. There were no significant changes in the incidence of rejection over time (linear trend p =0.11). The median time to the first episode of rejection was 71 days after LT: 2.2% hyperacute, 50.4% early (≤90 d), and 47.5% late rejection (>90 d). Independent risk factors for rejection were younger recipient age at transplant (aHR 0.98 per year increase, 95% CI: 0.97-1.00, p =0.01), and ABO-incompatible grafts (aHR 2.55 vs. ABO-compatible, 95% CI: 1.27-5.09, p <0.01) while simultaneous multiorgan transplants were protective (aHR 0.21 vs. LT only, 95% CI: 0.08-0.58, p <0.01). Development of acute rejection (both early and late) was independently associated with significantly reduced graft (aHR 3.13, 95% CI: 2.21-4.42, p <0.001) and patient survival (aHR 3.42, 95% CI: 2.35-4.98, p <0.001). In this 11-year Australian study, acute LT rejection occurred in 35%, with independent risk factors of younger recipient age and ABO-incompatible transplant, while having a simultaneous multiorgan transplant was protective. Acute rejection was independently associated with reduced graft and patient survival after adjustment for other factors.
背景:急性异体移植排斥反应是众所周知的肝移植并发症。在澳大利亚,急性排斥反应的发生率、流行病学和结果尚未得到很好的描述:我们回顾性地研究了2010-2020年间在一个中心接受过已故供体肝移植的连续成人患者。我们从前瞻性LT数据库中收集了LT时的供体和受体数据以及受体结果。对肝脏活检报告进行了审查,仅分析了移植物首次出现活检证实的急性排斥反应:在研究期间,共有770名患者接受了796例肝移植手术。34.9%的移植发生了活组织检查证实的排斥反应。随着时间的推移,排斥反应的发生率没有明显变化(线性趋势 p=0.11)。首次排斥反应的中位时间为移植后71天:2.2%为超急性排斥反应,50.4%为早期排斥反应(≤90天),47.5%为晚期排斥反应(>90天)。排斥反应的独立风险因素是移植时受者年龄较小(aHR 每年增加 0.98,95% CI 0.97-1.00,p=0.01),以及 ABO 不兼容移植物(aHR 2.55 vs. ABO 兼容,95% CI 1.27-5.09,p):在这项为期11年的澳大利亚研究中,急性LT排斥反应发生率为35%,其独立风险因素是受者年龄较小和ABO血型不相容,而同时进行多器官移植则具有保护作用。在对其他因素进行调整后,急性排斥反应与移植物和患者存活率的降低密切相关。
期刊介绍:
Since the first application of liver transplantation in a clinical situation was reported more than twenty years ago, there has been a great deal of growth in this field and more is anticipated. As an official publication of the AASLD, Liver Transplantation delivers current, peer-reviewed articles on liver transplantation, liver surgery, and chronic liver disease — the information necessary to keep abreast of this evolving specialty.